It is reported that relative abundance of mutant epidermal growth factor receptor (EGFR) can predict benefit from EGFR-tyrosine kinase inhibitors for advanced non-small-cell lung cancer [40]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.